Applying the unique opportunities of the G-Technology^® for chronic treatment, in combination with the ability to gain proof-of-concept in any animal model, to-BBB is now entering into several research collaborations around compounds of pharma partners for specific product-indication combinations, like Alzheimer’s-, Parkinson’s Disease, Multiple Sclerosis, Cancer, Stroke and Lysosomal Storage Diseases.  

Corporate partners:

Based on the G-Technology^®, to-BBB has several research collaborations on brain-delivery of compounds with (bio)pharmaceutical companies.

Abbott:

to-BBB has signed a research agreement with Abbott to evaluate an undisclosed indication.

Janssen:

to-BBB entered a pilot study with Janssen Pharmaceutica NV to enhance delivery of drugs to the brain for CNS diseases.

GSK:

to-BBB and GSK R&D China are collaborating on brain delivery of a biologic product.

Top 10 Pharma:

Two undisclosed Top 10 pharma companies have entered a research collaboration to evaluate undisclosed indications.

Lundbeck:

to-BBB and Lundbeck have entered into a research collaboration to evaluate delivery of antibodies to the brain for CNS diseases.

Genzyme:

to-BBB and Genzyme have entered into a research collaboration to evaluate to-BBB’s G-Technology to safely enhance the delivery of biologics for neurodegenerative diseases.

MedImmune:

Together with MedImmune, the worldwide biologics business for AstraZeneca, to-BBB has started a research program to evaluate to-BBB's G-Technology to safely deliver biologics to the brain.

Shire:

to-BBB has signed a research agreement with Shire Human Genetics to perform a feasibility project in the area of Lysosomal Storage Diseases. Enzyme Replacement Therapies have been developed for several Lysosomal Storage Diseases. Due to presence of the neuroprotective Blood-Brain Barrier these enzymes have limited effects on neurological symptoms of the disease. Shire and to-BBB will investigate whether to-BBB´s G-Technology^® can enhance delivery of enzyme to the brain to address this unmet medical need.

Academic partners:

Flanders Interuniversity Institute for Biotechnology, KU Leuven, Belgium:

Professor Bart de Strooper from the renowned Flanders Interuniversity Institute for Biotechnology (VIB) and KU Leuven is working with to-BBB on developing antibody-based therapies for the treatment of Alzheimer’s disease.

The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, the Netherlands:

The research group of Olaf van Tellingen from The Netherlands Cancer Institute- Antoni van Leeuwenhoek Hospital (NKI-AVL) in Amsterdam, collaborates with to-BBB for the development of brain-targeted liposomes with encapsulated anti-cancer drugs.

TNO / US Army, The Netherlands:

Together with TNO Defence, Security and Safety, to-BBB is investigating the enrichment of the blood-brain barrier and brain with the nerve agent bioscavenger Human ButyrylCholinesterase (HuBuChE) to improve its antidotal efficacy. The US Army Medical Research Institute of Chemical Defense funded this research project.

Industrial Technology Research Institute, Taiwan:

The Industrial Technology Research Institute of Taiwan (ITRI) is a national research organization that serves to strengthen the technological competitiveness of Taiwan. In addition to its internally developed patent estate, to-BBB signed an exclusive license agreement with ITRI, granting to-BBB the worldwide rights for the development and commercialization of the G-Technology^®. The G-Technology^® was developed in the Drug Delivery Department of Dr. Maggie Lu at the Biomedical Engineering Research Laboratories in Hsinchu City, and Dr. Lu continues to be a collaboration partner for to-BBB. 

Rega Institute for Medical Research, KU Leuven, Belgium:

For the viral encephalitis proof-of-concept work is performed at the Rega Institute. They are world-class leaders in the field of anti-viral therapies for encephalitis-causing viral agents.

Leiden University:

The proprietary HB-EGF-Technology™ (formerly 2B-Trans™) and the scientific and technological know-how on the blood-brain barrier, were developed by Pieter Gaillard and Bert de Boer within the Blood-Brain Barrier Research Group of Leiden University. All related IPR has been transferred to to-BBB. Currently, a Dutch Technology Foundation project entitled "Advanced Treatment of HIV Infection" is ongoing.